 Micol Rothman
Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 10 | 2023 | 242 | 3.910 |
Why?
| | Transgender Persons | 7 | 2025 | 187 | 2.750 |
Why?
| | Osteoporotic Fractures | 5 | 2024 | 61 | 2.480 |
Why?
| | Bone Density Conservation Agents | 9 | 2024 | 82 | 2.230 |
Why?
| | Estradiol | 5 | 2025 | 525 | 1.310 |
Why?
| | Transsexualism | 2 | 2021 | 20 | 1.300 |
Why?
| | Absorptiometry, Photon | 5 | 2023 | 264 | 1.290 |
Why?
| | Bone Density | 6 | 2022 | 489 | 1.040 |
Why?
| | Bone Diseases, Metabolic | 3 | 2024 | 64 | 1.030 |
Why?
| | Hyperandrogenism | 2 | 2021 | 21 | 1.020 |
Why?
| | Testosterone | 6 | 2025 | 402 | 0.880 |
Why?
| | Postmenopause | 4 | 2021 | 370 | 0.750 |
Why?
| | Interdisciplinary Placement | 1 | 2020 | 2 | 0.660 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.630 |
Why?
| | Telecommunications | 1 | 2019 | 21 | 0.620 |
Why?
| | Sexual and Gender Minorities | 1 | 2023 | 229 | 0.620 |
Why?
| | Education, Medical, Continuing | 1 | 2020 | 132 | 0.600 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1567 | 0.590 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 334 | 0.490 |
Why?
| | Diphosphonates | 2 | 2019 | 69 | 0.470 |
Why?
| | Quality Improvement | 1 | 2023 | 1213 | 0.450 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 370 | 0.450 |
Why?
| | Coronavirus Infections | 1 | 2020 | 367 | 0.450 |
Why?
| | Hypogonadism | 3 | 2013 | 92 | 0.450 |
Why?
| | Denosumab | 3 | 2024 | 9 | 0.430 |
Why?
| | Mass Media | 1 | 2014 | 45 | 0.420 |
Why?
| | Glucocorticoids | 3 | 2024 | 528 | 0.420 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2024 | 42 | 0.400 |
Why?
| | Estrone | 2 | 2010 | 36 | 0.370 |
Why?
| | Spinal Fractures | 2 | 2024 | 74 | 0.360 |
Why?
| | Humans | 38 | 2025 | 138651 | 0.340 |
Why?
| | Telemedicine | 1 | 2020 | 873 | 0.340 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 281 | 0.340 |
Why?
| | Fibrous Dysplasia, Polyostotic | 1 | 2010 | 8 | 0.340 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2013 | 176 | 0.340 |
Why?
| | Dihydrotestosterone | 1 | 2010 | 44 | 0.340 |
Why?
| | Facial Bones | 1 | 2010 | 30 | 0.330 |
Why?
| | Mass Screening | 2 | 2021 | 1292 | 0.330 |
Why?
| | Injections, Subcutaneous | 3 | 2025 | 162 | 0.330 |
Why?
| | Injections, Intramuscular | 3 | 2025 | 130 | 0.320 |
Why?
| | Menstrual Cycle | 1 | 2010 | 133 | 0.310 |
Why?
| | Gender Identity | 2 | 2021 | 126 | 0.300 |
Why?
| | Skull | 1 | 2010 | 150 | 0.300 |
Why?
| | Female | 22 | 2025 | 73763 | 0.290 |
Why?
| | Hypothalamo-Hypophyseal System | 2 | 2024 | 205 | 0.290 |
Why?
| | Male | 21 | 2025 | 68260 | 0.260 |
Why?
| | Infertility | 1 | 2007 | 55 | 0.260 |
Why?
| | Neurosecretory Systems | 1 | 2007 | 31 | 0.260 |
Why?
| | Adult | 16 | 2025 | 38201 | 0.240 |
Why?
| | Ovary | 1 | 2008 | 223 | 0.240 |
Why?
| | Hypoparathyroidism | 1 | 2025 | 6 | 0.240 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2007 | 212 | 0.240 |
Why?
| | Bone Remodeling | 1 | 2024 | 77 | 0.220 |
Why?
| | Adrenal Insufficiency | 1 | 2024 | 29 | 0.210 |
Why?
| | Thromboembolism | 1 | 2024 | 117 | 0.200 |
Why?
| | Cohort Studies | 2 | 2023 | 5697 | 0.190 |
Why?
| | Brain Injuries | 1 | 2007 | 501 | 0.180 |
Why?
| | Aged | 9 | 2025 | 24024 | 0.170 |
Why?
| | Androgens | 2 | 2013 | 186 | 0.170 |
Why?
| | Academic Medical Centers | 1 | 2023 | 514 | 0.170 |
Why?
| | Teriparatide | 3 | 2025 | 9 | 0.160 |
Why?
| | Hydrocortisone | 2 | 2024 | 314 | 0.160 |
Why?
| | Hormones | 1 | 2021 | 140 | 0.160 |
Why?
| | Osteitis Deformans | 1 | 2020 | 7 | 0.160 |
Why?
| | Fractures, Compression | 1 | 2020 | 15 | 0.160 |
Why?
| | Osteolysis | 1 | 2020 | 18 | 0.160 |
Why?
| | Self Administration | 1 | 2020 | 126 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2049 | 0.160 |
Why?
| | Prostatic Neoplasms | 1 | 2007 | 1044 | 0.160 |
Why?
| | Comprehensive Health Care | 1 | 2019 | 23 | 0.160 |
Why?
| | Pyrazoles | 2 | 2013 | 425 | 0.150 |
Why?
| | Health Services for the Aged | 1 | 2019 | 72 | 0.150 |
Why?
| | Pyridines | 2 | 2013 | 494 | 0.150 |
Why?
| | Self Report | 1 | 2023 | 839 | 0.150 |
Why?
| | Bone and Bones | 1 | 2021 | 317 | 0.150 |
Why?
| | Hip Fractures | 1 | 2019 | 86 | 0.150 |
Why?
| | House Calls | 1 | 2020 | 141 | 0.140 |
Why?
| | Spinal Stenosis | 1 | 2018 | 31 | 0.140 |
Why?
| | Retrospective Studies | 7 | 2025 | 15909 | 0.140 |
Why?
| | Referral and Consultation | 1 | 2023 | 793 | 0.140 |
Why?
| | Anorexia Nervosa | 1 | 2019 | 90 | 0.140 |
Why?
| | Back Pain | 1 | 2018 | 52 | 0.140 |
Why?
| | Middle Aged | 14 | 2025 | 33604 | 0.140 |
Why?
| | HIV Infections | 1 | 2012 | 2941 | 0.140 |
Why?
| | Progesterone | 1 | 2019 | 258 | 0.140 |
Why?
| | Anesthetics, Local | 1 | 2018 | 98 | 0.130 |
Why?
| | Aged, 80 and over | 4 | 2023 | 7677 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 272 | 0.130 |
Why?
| | Pelvic Bones | 1 | 2019 | 128 | 0.130 |
Why?
| | Curriculum | 1 | 2023 | 1009 | 0.130 |
Why?
| | Protein Kinase Inhibitors | 2 | 2013 | 907 | 0.130 |
Why?
| | Primary Health Care | 2 | 2023 | 1777 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2011 | 1482 | 0.120 |
Why?
| | Sexual Behavior | 1 | 2019 | 488 | 0.110 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 496 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2020 | 958 | 0.100 |
Why?
| | Surveys and Questionnaires | 2 | 2023 | 5803 | 0.090 |
Why?
| | Quality of Life | 2 | 2021 | 2954 | 0.090 |
Why?
| | Hirsutism | 1 | 2011 | 12 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1641 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2013 | 2152 | 0.090 |
Why?
| | Prevalence | 2 | 2019 | 2727 | 0.080 |
Why?
| | Injections, Intravenous | 1 | 2010 | 202 | 0.080 |
Why?
| | Imidazoles | 1 | 2010 | 239 | 0.080 |
Why?
| | Reference Values | 1 | 2010 | 799 | 0.070 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 448 | 0.070 |
Why?
| | Pituitary Hormones | 1 | 2008 | 16 | 0.070 |
Why?
| | Amenorrhea | 1 | 2008 | 31 | 0.070 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2012 | 357 | 0.070 |
Why?
| | Kisspeptins | 1 | 2007 | 6 | 0.070 |
Why?
| | Endocrine Glands | 1 | 2007 | 16 | 0.070 |
Why?
| | Thyroid Hormones | 1 | 2008 | 60 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 555 | 0.070 |
Why?
| | Pituitary Hormones, Anterior | 1 | 2007 | 7 | 0.070 |
Why?
| | Pituitary Gland, Anterior | 1 | 2007 | 38 | 0.070 |
Why?
| | Hypothalamus | 1 | 2007 | 153 | 0.060 |
Why?
| | Prolactin | 1 | 2007 | 96 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2013 | 1111 | 0.060 |
Why?
| | Gonadal Steroid Hormones | 1 | 2008 | 138 | 0.060 |
Why?
| | Thyrotropin | 1 | 2007 | 117 | 0.060 |
Why?
| | Adrenocorticotropic Hormone | 1 | 2007 | 148 | 0.060 |
Why?
| | Incidence | 1 | 2012 | 2747 | 0.060 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2007 | 220 | 0.060 |
Why?
| | Calcitriol | 1 | 2025 | 59 | 0.060 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5520 | 0.060 |
Why?
| | Tumor Suppressor Proteins | 1 | 2007 | 320 | 0.060 |
Why?
| | Young Adult | 3 | 2025 | 13305 | 0.060 |
Why?
| | Parathyroid Hormone | 1 | 2025 | 111 | 0.060 |
Why?
| | Withholding Treatment | 1 | 2024 | 77 | 0.050 |
Why?
| | Endocrinologists | 1 | 2024 | 13 | 0.050 |
Why?
| | Lumbar Vertebrae | 1 | 2024 | 249 | 0.050 |
Why?
| | Pituitary-Adrenal System | 1 | 2024 | 170 | 0.050 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2022 | 25 | 0.050 |
Why?
| | Paroxetine | 1 | 2000 | 11 | 0.040 |
Why?
| | Antidepressive Agents, Second-Generation | 1 | 2000 | 50 | 0.040 |
Why?
| | Receptor Activator of Nuclear Factor-kappa B | 1 | 2020 | 9 | 0.040 |
Why?
| | RANK Ligand | 1 | 2020 | 29 | 0.040 |
Why?
| | Double-Blind Method | 3 | 2018 | 1949 | 0.040 |
Why?
| | Calcium | 1 | 2025 | 1180 | 0.040 |
Why?
| | Outpatient Clinics, Hospital | 1 | 1999 | 82 | 0.040 |
Why?
| | Nicotinic Agonists | 1 | 2000 | 134 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2025 | 10923 | 0.040 |
Why?
| | Calcium, Dietary | 1 | 2019 | 57 | 0.040 |
Why?
| | Drug Therapy, Combination | 2 | 2018 | 1032 | 0.040 |
Why?
| | Health Status Indicators | 1 | 1999 | 163 | 0.040 |
Why?
| | Adolescent | 2 | 2019 | 21564 | 0.040 |
Why?
| | Risk Factors | 1 | 2012 | 10252 | 0.040 |
Why?
| | Triamcinolone | 1 | 2018 | 13 | 0.040 |
Why?
| | Health Status | 1 | 2024 | 819 | 0.040 |
Why?
| | Injections, Epidural | 1 | 2018 | 28 | 0.040 |
Why?
| | Betamethasone | 1 | 2018 | 21 | 0.040 |
Why?
| | Tobacco Use Disorder | 1 | 2000 | 245 | 0.040 |
Why?
| | Methylprednisolone | 1 | 2018 | 63 | 0.030 |
Why?
| | United States | 2 | 2025 | 14938 | 0.030 |
Why?
| | Lidocaine | 1 | 2018 | 53 | 0.030 |
Why?
| | Nicotine | 1 | 2000 | 347 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2749 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2019 | 186 | 0.030 |
Why?
| | Smoking Cessation | 1 | 2000 | 436 | 0.030 |
Why?
| | Survival Analysis | 1 | 2019 | 1309 | 0.030 |
Why?
| | Eating | 1 | 2019 | 392 | 0.030 |
Why?
| | Estrogen Replacement Therapy | 1 | 1996 | 140 | 0.030 |
Why?
| | Dexamethasone | 1 | 2018 | 375 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 548 | 0.030 |
Why?
| | Vitamin D | 1 | 2019 | 393 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1436 | 0.030 |
Why?
| | Body Composition | 1 | 2019 | 694 | 0.030 |
Why?
| | Pain Management | 1 | 2018 | 389 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2022 | 1092 | 0.030 |
Why?
| | Signal Transduction | 1 | 2007 | 5086 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 4092 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 53 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 24 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 47 | 0.020 |
Why?
| | Luteinizing Hormone | 1 | 2013 | 183 | 0.020 |
Why?
| | Serum Albumin | 1 | 2013 | 151 | 0.020 |
Why?
| | Ethanol | 1 | 1996 | 614 | 0.020 |
Why?
| | Follicle Stimulating Hormone | 1 | 2013 | 243 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 349 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 215 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1996 | 808 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 666 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 643 | 0.020 |
Why?
| | Patient Compliance | 2 | 2000 | 598 | 0.010 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 777 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2012 | 3523 | 0.010 |
Why?
| | Cytokines | 1 | 2012 | 2080 | 0.010 |
Why?
| | Animals | 1 | 2007 | 37217 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3139 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2349 | 0.010 |
Why?
| | Administration, Cutaneous | 1 | 2000 | 128 | 0.010 |
Why?
| | Sampling Studies | 1 | 1999 | 101 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2013 | 2527 | 0.010 |
Why?
| | Sickness Impact Profile | 1 | 1999 | 57 | 0.010 |
Why?
| | North Carolina | 1 | 1999 | 120 | 0.010 |
Why?
| | Hospitals, Veterans | 1 | 1999 | 255 | 0.010 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2000 | 184 | 0.010 |
Why?
| | Health Care Surveys | 1 | 1999 | 565 | 0.010 |
Why?
| | Medroxyprogesterone Acetate | 1 | 1996 | 35 | 0.010 |
Why?
| | Analysis of Variance | 1 | 1999 | 1317 | 0.010 |
Why?
| | Cross-Over Studies | 1 | 1996 | 556 | 0.010 |
Why?
| | Depression | 1 | 2000 | 1466 | 0.010 |
Why?
|
|
Rothman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|